Adamson-Small Laura, Potter Mark, Byrne Barry J, Clément Nathalie
Department of Pediatrics, Powell Gene Therapy Center, University of Florida , Gainesville, FL.
Hum Gene Ther Methods. 2017 Feb;28(1):1-14. doi: 10.1089/hgtb.2016.151.
The increase in effective treatments using recombinant adeno-associated viral (rAAV) vectors has underscored the importance of scalable, high-yield manufacturing methods. Previous work from this group reported the use of recombinant herpes simplex virus type 1 (rHSV) vectors to produce rAAV in adherent HEK293 cells, demonstrating the capacity of this system and quality of the product generated. Here we report production and optimization of rAAV using the rHSV system in suspension HEK293 cells (Expi293F) grown in serum and animal component-free medium. Through adjustment of salt concentration in the medium and optimization of infection conditions, titers greater than 1 × 10 vector genomes per liter (VG/liter) were observed in purified rAAV stocks produced in Expi293F cells. Furthermore, this system allowed for high-titer production of multiple rAAV serotypes (2, 5, and 9) as well as multiple transgenes (green fluorescent protein and acid α-glucosidase). A proportional increase in vector production was observed as this method was scaled, with a final 3-liter shaker flask production yielding an excess of 1 × 10 VG in crude cell harvests and an average of 3.5 × 10 total VG of purified rAAV9 material, resulting in greater than 1 × 10 VG/cell. These results support the use of this rHSV-based rAAV production method for large-scale preclinical and clinical vector production.
使用重组腺相关病毒(rAAV)载体的有效治疗方法的增加凸显了可扩展的高产制造方法的重要性。该研究小组之前的工作报道了使用重组1型单纯疱疹病毒(rHSV)载体在贴壁HEK293细胞中生产rAAV,证明了该系统的能力以及所产生产品的质量。在此,我们报道了在无血清和无动物成分培养基中培养的悬浮HEK293细胞(Expi293F)中使用rHSV系统生产和优化rAAV的情况。通过调整培养基中的盐浓度和优化感染条件,在Expi293F细胞中产生的纯化rAAV储备液中观察到滴度大于每升1×10载体基因组(VG/升)。此外,该系统允许高滴度生产多种rAAV血清型(2、5和9)以及多种转基因(绿色荧光蛋白和酸性α-葡萄糖苷酶)。随着该方法规模扩大,观察到载体产量成比例增加,最终3升摇瓶生产在粗细胞收获物中产生超过1×10 VG,纯化的rAAV9材料平均总VG为3.5×10,导致每个细胞大于1×10 VG。这些结果支持使用这种基于rHSV的rAAV生产方法进行大规模临床前和临床载体生产。